Stockscreener 앱 받기
1.20
0.01%
0.000100
시간 외 거래:
1.20
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Plus Therapeutics appoints new Chief Development Officer By Investing.com - Investing.com Nigeria
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer - citybiz
Plus Therapeutics appoints new Chief Development Officer - Investing.com India
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer's Candidate, Zervimesine (CT1812) - The Manila Times
Can This Veteran Drug Developer Transform Plus Therapeutics' Clinical Pipeline? - StockTitan
Stromal Vascular Fraction Market Set to Grow Significantly, - GlobeNewswire
Plus Therapeutics, Inc. Appoints Michael Rosol as Chief Development Officer -February 20, 2025 at 07:30 am EST - Marketscreener.com
Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program - GlobeNewswire
Plus Therapeutics secures $5.7 million for cancer trials - Investing.com India
Plus Therapeutics Secures $3.7M in Convertible Notes Deal - TipRanks
Plus Therapeutics Secures $3.7 Million in Private Placement Financing and $2.0 Million Advance from CPRIT for Clinical Development of CNS Cancer Treatments - Nasdaq
Plus Therapeutics Lands $5.7M Strategic Investment to Accelerate Cancer Treatment Breakthrough - StockTitan
Week Ahead (Aug.16-20): FATE, PSTV To Present Data, Will AXSM Get FDA Nod? - RTTNews
Plus Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights - br.ADVFN.com
Plus Therapeutics (NASDAQ:PSTV) Shares Down 1.3% – Here’s Why - Defense World
CARsgen's First Enrolled Subject in the THANK-u Plus™ Platform-Based Allogeneic CAR-T Trial Achieves sCR at Week 4 - Yahoo Finance
The CRISPR companies are not OK - STAT
Glioma Market Anticipated to Expand Rapidly During 2024-2034, Says DelveInsight - EIN News
LD Micro 360 Companies Set to Present this Week - ACCESS Newswire
Elevar Therapeutics Presents Results from Post-Hoc Analysis of CARES-310 Study Evaluating the Impact of Viral and Non-Viral Etiology on Survival in Hepatocellular Carcinoma - Yahoo Finance
MiNK Therapeutics Targets Immune Reconstitution to Combat - GlobeNewswire
MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI - Yahoo Finance UK
Leptomeningeal Metastases Pipeline Analysis, Clinical - openPR
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Epidemiology, Medication, and Companies by DelveInsight - The Globe and Mail
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA - openPR
Eli Lilly acquires cancer program from Scorpion Therapeutics in $2.5B deal - STAT
Exclusive-Blackstone mulls $4 billion-plus sale of Liftoff, sources say - Yahoo Finance
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, - openPR
Exclusive: Warburg Pincus explores $5 billion-plus sale of Modernizing Medicine, sources say - Reuters
Stevanato Group (NYSE:STVN) & Plus Therapeutics (NASDAQ:PSTV) Head to Head Review - Defense World
Are Broader Antibody Patents Possible in US Through Means-Plus-Function Claiming? - JD Supra
Simulations Plus (SLP) Fell due to Concerns Over the Funding Environment - Yahoo Finance
STAT6 stat sig? Kaken, J&J $1.2B-plus deal adds oomph to space - BioWorld Online
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Sermonix and Henlius Dose First Chinese Patient in Phase 3 - GlobeNewswire
FDA Tracker: 2024 Ends With Lilly’s Landmark GLP-1 Sleep Apnea Approval - BioSpace
PSTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Poseida Therapeutics, Inc. Is Fair to Shareholders - Business Wire
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire
Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan
PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich’s Ataxia - GlobeNewswire
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients - Yahoo Finance
Investors in Padlock Therapeutics sue Bristol Myers Squibb over ‘milestone’ payments - STAT
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire
IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia - OncLive
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Roche Launches $9/Share Cash Tender Offer for Poseida Therapeutics, CVR Could Add $4 More - StockTitan
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire
Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan
Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire
Plus Therapeutics Secures 5-Year Supply Deal for Key Cancer Treatment Radioisotope - StockTitan
HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World
Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details - Yahoo Finance
CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network
Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan
PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan
PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
0.27%
3.05%
자본화:
|
볼륨(24시간):